New pill takes aim at Hard-to-Treat cancers
NCT ID NCT06586957
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This early-stage trial tests an experimental pill, NKT3964, designed to break down a protein called CDK2 that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have not responded to standard treatments will take the drug. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Cancer Institute
RECRUITINGOrlando, Florida, 32804, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Augusta University
NOT_YET_RECRUITINGAugusta, Georgia, 30912, United States
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Florida Cancer Specialists & Research Institute
TERMINATEDLake Mary, Florida, 32746, United States
-
Intermountain Health
RECRUITINGSalt Lake City, Utah, 84145, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center at Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGAustin, Texas, 78758, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sarah Cannon Research Institute (SCRI)
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sidney Kimmell Cancer Center - Jefferson Health
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Contact Phone: •••-•••-••••
-
UCSF
WITHDRAWNSan Francisco, California, 94158, United States
-
UPMC
WITHDRAWNPittsburgh, Pennsylvania, 15213, United States
-
UT Southwestern
RECRUITINGDallas, Texas, 75235, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Arkansas Medical School
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California - Los Angeles
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
Contact
-
University of Kansas
WITHDRAWNFairway, Kansas, 66205, United States
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.